Meet Jill Thompson, a blind Benedictine oblate who serves as a lector at St. Scholastica Monastery. She shares sacred texts with devotion and grace.

Atlanta Catholics recalled the life and legacy of Dr. Martin Luther King Jr. with an archdiocesan Mass and at a special ...

Q: I am a 14-year-old boy, and growing up I learned to serve the Mass. At first I never served with girls (my old church did ...

Alex Flaten was Rush City High School’s nominee for the Minnesota State High School League’s Academics, Arts and Athletics ...

The fair value estimate for Alector has shifted slightly, moving from 2.05 to 2.10, while the discount rate has also adjusted from 7.54% to 7.39%, even as the revenue growth assumption remains ...

The latest announcement is out from Alector ( (ALEC)). On December 10, 2025, Alector appointed Neil Berkley as Chief Financial Officer, a role he has been serving in an interim capacity since June ...

The world-famous psychological thriller The Silence of the Lambs will visit Blackpool Grand Theatre in the form of a new stage play, it has been announced. This landmark new production thrusts ...

Alector's consensus analyst price target has recently dropped from $2.20 to $2.05 per share, signaling reduced confidence in the company's near-term outlook. This adjustment comes after the release of ...

Lectorum Publications, the largest independent distributor of Spanish-language books in the U.S., will close after more than 60 years in business, with its inventory of approximately 700,000 books ...

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating ...

Alector, a once-high-flying Bay Area biotech company that researches treatments for degenerative brain disorders like Parkinson’s and Alzheimer’s diseases, is laying off about half of its staff. The ...

Oct 21 (Reuters) - Alector (ALEC.O), opens new tab said on Tuesday its experimental drug failed to slow the progression of a rare form of dementia in a late-stage trial, prompting the company to end ...